Stingray Therapeutics is focused on developing next-generation immunotherapies aimed at combating cancer by targeting the ENPP1 protein, which plays a critical role in the regulation of the immune response. The company’s approach involves the activation of the cGAS-STING pathway, which is initiated when cytoplasmic double-stranded DNA (dsDNA) is recognized by the cGAS enzyme. This recognition leads to the production of 2’3’ cGAMP, a natural ligand for STING. However, ENPP1 negatively regulates this pathway by degrading 2’3’ cGAMP into AMP and GMP, with AMP further converted into adenosine, a molecule known to suppress immune activity within the tumor microenvironment.

The upregulation of ENPP1 is particularly significant in metastatic tumors, where it has been associated with reduced immune cell infiltration, increased metastasis, and resistance to both chemotherapy and adaptive immunotherapies. By targeting ENPP1, Stingray Therapeutics aims to enhance the immune system's ability to fight cancer more effectively, potentially overcoming the challenges posed by tumor-induced immune suppression. The company has presented its findings at various scientific conferences, including AACR 2020, 2023, and 2024, highlighting the importance of their research in the field of cancer immunotherapy.

United States

Stingray Therapeutics is working on an exciting new effort to fight cancer with 2nd generation immune-oncology agents. Current efforts in this field are the equivalent of trying to do it with one hand of the immune system tied behind its back. At Stingray, we are unleashing the full immune system to take this fight to an entirely new level.

The first generation of immune-oncology therapies, checkpoint inhibitors, leverage adaptive immunity to counter cancer’s immunosuppressive “checkpoints.” However, many patients develop resistance or are non- responsive to treatment given tumors are “cold” (cancer unrecognized by adaptive immune system).



Stingray Therapeutics

Company Details